{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pyridoxine+hydrochloride&page=2", "query": { "intervention": "Pyridoxine hydrochloride", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pyridoxine+hydrochloride&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pyridoxine+hydrochloride&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T22:39:51.739Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02758990", "title": "Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Rhinitis", "Rhinitis, Allergic", "Respiratory Sounds", "Dyspnea", "Headache", "Migraine Disorders", "Arthritis", "Arthralgia", "Anxiety", "Sleep Initiation and Maintenance Disorders", "Sleep Deprivation" ], "interventions": [ { "name": "Vitamin A", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin B6", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" }, { "name": "Nicotinamide", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin D3", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin E", "type": "DIETARY_SUPPLEMENT" }, { "name": "Broccoli", "type": "OTHER" }, { "name": "Spinach", "type": "OTHER" }, { "name": "Caffeine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Coffee", "type": "OTHER" }, { "name": "Axon Eyewear", "type": "DEVICE" }, { "name": "Chocolate", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DEVICE" ], "sponsor": "Verifomics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-03", "completion_date": "2016-11-23", "has_results": false, "last_update_posted_date": "2017-10-02", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02758990" }, { "nct_id": "NCT01404312", "title": "Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis", "HIV Infections" ], "interventions": [ { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 3000, "start_date": "2012-05-23", "completion_date": "2017-11-14", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01404312" }, { "nct_id": "NCT02410772", "title": "TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis" ], "interventions": [ { "name": "rifapentine", "type": "DRUG" }, { "name": "rifapentine and moxifloxacin", "type": "DRUG" }, { "name": "control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 2516, "start_date": "2016-01-25", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 5, "location_summary": "San Francisco, California • New York, New York • Fort Worth, Texas + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Fort Worth", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410772" }, { "nct_id": "NCT03738943", "title": "Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Receptor Blockade" ], "interventions": [ { "name": "Adenosine Triphosphate", "type": "DRUG" }, { "name": "Acetylcholine", "type": "DRUG" }, { "name": "Sodium Nitroprusside", "type": "DRUG" }, { "name": "Adenosine Diphosphate", "type": "DRUG" }, { "name": "Adenosine Monophosphate", "type": "DRUG" }, { "name": "Uridine Triphosphate", "type": "DRUG" }, { "name": "Adenosine", "type": "DRUG" }, { "name": "Vitamin B 6", "type": "DRUG" }, { "name": "Pyridoxal 5'-Phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "18 Years to 30 Years" }, "enrollment_count": 9, "start_date": "2019-02-07", "completion_date": "2021-06-01", "has_results": false, "last_update_posted_date": "2021-07-27", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 1, "location_summary": "Fort Collins, Colorado", "locations": [ { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03738943" }, { "nct_id": "NCT00001033", "title": "The Treatment of Tuberculosis in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Ethambutol hydrochloride", "type": "DRUG" }, { "name": "Isoniazid", "type": "DRUG" }, { "name": "Pyrazinamide", "type": "DRUG" }, { "name": "Pyridoxine hydrochloride", "type": "DRUG" }, { "name": "Levofloxacin", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 650, "start_date": null, "completion_date": "1997-07", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 12, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001033" }, { "nct_id": "NCT01795170", "title": "Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pyridoxine Dependant Epilepsy" ], "interventions": [ { "name": "Lysine Restricted Diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Pyridoxine", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "University of British Columbia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "3 Years", "sex": "ALL", "summary": "3 Months to 3 Years" }, "enrollment_count": 0, "start_date": "2013-04", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2014-09-30", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 2, "location_summary": "Aurora, Colorado • Seattle, Washington", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01795170" }, { "nct_id": "NCT00877812", "title": "Vitamin B6 Dependence of One-Carbon Metabolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vitamin B6 Deficiency" ], "interventions": [ { "name": "Arm 1 glycine and leucine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Arm 2 Intervention of Serine and methionine infusion", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "20 Years to 40 Years" }, "enrollment_count": 45, "start_date": "2008-01", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877812" }, { "nct_id": "NCT05411744", "title": "One-month Latent Tuberculosis Treatment for Renal Transplant Candidates", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Latent Tuberculosis", "End Stage Renal Disease", "Renal Transplant Candidate for Right Kidney", "Renal Transplant Candidate for Left Kidney" ], "interventions": [ { "name": "1 month Rifapentine, Isoniazid and Vitamin B6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 25, "start_date": "2022-07-01", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05411744" }, { "nct_id": "NCT05363410", "title": "Micronutrient Supplement for Nurse Burnout", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Burnout, Professional", "Stress, Psychological" ], "interventions": [ { "name": "MagnéVie B6®", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Nutraceuticals Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "59 Years", "sex": "FEMALE", "summary": "20 Years to 59 Years · Female only" }, "enrollment_count": 88, "start_date": "2022-05-01", "completion_date": "2023-04-30", "has_results": false, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 1, "location_summary": "Franklin, Tennessee", "locations": [ { "city": "Franklin", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363410" }, { "nct_id": "NCT00032435", "title": "Homocysteine Study (HOST)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "End Stage Renal Disease", "Renal Failure" ], "interventions": [ { "name": "PAL-40 Active", "type": "DRUG" }, { "name": "PAL-40 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2003, "start_date": "2001-05", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2010-10-15", "last_synced_at": "2026-10-04T22:39:51.739Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Menlo Park", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00032435" } ] }